🧫

Phase I trial of NP137 in advanced endometrial cancer

experiment Created: 2026-04-10 14:41:11 By: experiment_extractor Quality: 95% ✓ SciDEX ID: experiment-exp-0854c675-3027-47a4-971e-0
🧫 Experiment Protocol Clinical Trial
🧫 View Full Experiment Page →
Related Entities
NTN1
Metadata
experiment_typeclinical_trial
protocolPhase I dose-escalation trial with NP137 monotherapy
expected_outcomesDemonstrated safety and clinical activity in advanced EC
success_criteriaObjective response rate and stable disease achievement
sample_size14
statistical_methodsRECIST v.1.1 response criteria
p_valueNone
effect_size57.1% stable disease rate, 7.1% objective response rate
extracted_at2026-04-10T07:41:11.301545
source_pmid37532934
_origin{'type': 'internal', 'url': None, 'tracked_at': '2026-04-10T14:41:11.364750'}
🌍 Provenance Graph 2 nodes, 1 edges

derives from (1)

Linked Artifacts (22)
derives_from📄Netrin-1 blockade inhibits tumour growth and EMT features in100%
related🧫Multi-omics analysis of NP137 mechanism in patient biopsies100%
related🧫Anti-netrin-1 antibody efficacy in EC mouse model100%
related🧫NP137 antibody treatment effects on EMT and metastasis in mo100%
related🧫Combination therapy with NP137 and carboplatin-paclitaxel100%
related🧪Netrin-1 Gradient Restoration100%
mentions📖NTN1 Gene - Netrin 180%
related📖NTN1 Gene - Netrin 172%
mentions📖Cancer60%
related🧫NP137 treatment of A549 human cancer cell xenografts60%
related🧫Netrin-1 expression analysis in human endometrial carcinomas60%
related🧫Multi-omics analysis of NP137 mechanism in patient biopsies60%
related🧫Anti-netrin-1 antibody efficacy in EC mouse model60%
related🧫NP137 antibody treatment effects on EMT and metastasis in mo60%
related🧫Combination therapy with NP137 and carboplatin-paclitaxel60%
related🧪Netrin-1 Gradient Restoration60%
related📖Cancer54%
mentions📖Protein Aggregation Seeding50%
mentions📖Netrin Signaling Pathway in Neurodegeneration50%
mentions📖Septal Nuclei Neurons44%
mentions📖Axon Guidance in 4R-Tauopathies44%
mentions📖PD Therapeutic Approaches Scorecard44%